Clinical trial
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of HCV-796 in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults
NCT00314054 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of HCV-796 in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 31, 2006
- Completion date
- October 31, 2007
- Enrollment
- 27 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.